JP2024517917A5 - - Google Patents

Info

Publication number
JP2024517917A5
JP2024517917A5 JP2023569634A JP2023569634A JP2024517917A5 JP 2024517917 A5 JP2024517917 A5 JP 2024517917A5 JP 2023569634 A JP2023569634 A JP 2023569634A JP 2023569634 A JP2023569634 A JP 2023569634A JP 2024517917 A5 JP2024517917 A5 JP 2024517917A5
Authority
JP
Japan
Prior art keywords
methyl
triazine
amino
hydroxy
piperidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/062525 external-priority patent/WO2022238347A1/en
Publication of JP2024517917A publication Critical patent/JP2024517917A/ja
Publication of JP2024517917A5 publication Critical patent/JP2024517917A5/ja
Pending legal-status Critical Current

Links

JP2023569634A 2021-05-12 2022-05-10 Nlrp3阻害剤 Pending JP2024517917A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21173452.0 2021-05-12
EP21173452 2021-05-12
EP21209447 2021-11-22
EP21209447.8 2021-11-22
EP21215859.6 2021-12-20
EP21215859 2021-12-20
PCT/EP2022/062525 WO2022238347A1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors

Publications (2)

Publication Number Publication Date
JP2024517917A JP2024517917A (ja) 2024-04-23
JP2024517917A5 true JP2024517917A5 (https=) 2025-04-30

Family

ID=81941106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569634A Pending JP2024517917A (ja) 2021-05-12 2022-05-10 Nlrp3阻害剤

Country Status (25)

Country Link
US (1) US20240208928A1 (https=)
EP (2) EP4337652B1 (https=)
JP (1) JP2024517917A (https=)
KR (1) KR20240007152A (https=)
AR (1) AR125818A1 (https=)
AU (1) AU2022275300A1 (https=)
BR (1) BR112023023527A2 (https=)
CA (1) CA3214626A1 (https=)
CL (1) CL2023003312A1 (https=)
CO (1) CO2023016204A2 (https=)
CR (1) CR20230529A (https=)
DK (1) DK4337652T3 (https=)
ES (1) ES3031704T3 (https=)
FI (1) FI4337652T3 (https=)
HR (1) HRP20250632T1 (https=)
HU (1) HUE071498T2 (https=)
IL (1) IL307188A (https=)
LT (1) LT4337652T (https=)
MA (1) MA64323B1 (https=)
MX (1) MX2023012907A (https=)
PE (1) PE20240126A1 (https=)
PL (1) PL4337652T3 (https=)
RS (1) RS66893B1 (https=)
SI (1) SI4337652T1 (https=)
WO (1) WO2022238347A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL314025A (en) * 2022-01-07 2024-08-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2023371859A1 (en) * 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
PE20251845A1 (es) * 2022-12-07 2025-07-17 Hoffmann La Roche Compuestos novedosos como moduladores de la inhibicion de nlrp3
WO2024158941A2 (en) * 2023-01-27 2024-08-02 Mwyngil Therapeutics, Inc. Inhibitors of nlrp3
JP2026511027A (ja) * 2023-03-20 2026-04-10 インシリコ メディスン アイピー リミティド Nlrp3インフラマソーム阻害剤及びその使用
WO2024193699A1 (zh) 2023-03-23 2024-09-26 成都赜灵生物医药科技有限公司 三嗪类化合物及其用途
KR20260027946A (ko) 2023-06-02 2026-03-03 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
IL324489A (en) 2023-06-29 2026-01-01 Hoffmann La Roche Triazine derivatives as NLRP3 inhibitors
CN121586712A (zh) 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3

Similar Documents

Publication Publication Date Title
JP2024517917A5 (https=)
HRP20250632T1 (hr) Nlrp3 inhibitori
US11034685B2 (en) Aminopyridine derivatives as TAM family kinase inhibitors
US10030027B2 (en) Soluble guanylate cyclase stimulators
JP2024522494A5 (https=)
US9688672B2 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
JP2024540445A5 (https=)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2020530446A5 (https=)
US8822510B2 (en) Substituted 3-phenyl-1,2,4-Oxadiazole compounds
JP2023506642A5 (https=)
US20160237059A1 (en) Heterocyclic substituted trifluoromethyl pyrimidinones and their use
JP5781611B2 (ja) Lrrk2キナーゼ阻害剤としての2−(ベンジルオキシ)ベンズアミド類
RU2005106844A (ru) [1,2,4]оксодиазолы (варианты), способ их получения, и фармацевтическая композиция и способ (варианты) ингибирования активации метаботропных глютаматных рецепторов-5
US8399451B2 (en) Heterocyclic compounds
JP2014523400A5 (https=)
EP2635573B1 (en) Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
RU2016121854A (ru) Производные гетероарила
US9187437B2 (en) Substituted oxadiazole compounds
JP2014513122A5 (https=)
US8835470B2 (en) Mandelamide heterocyclic compounds
US11851425B2 (en) Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines
JPWO2020100959A5 (https=)
RU2023132740A (ru) Ингибиторы nlrp3
JP2006523674A (ja) 慢性閉塞性肺疾患(copd)のための組合せ治療法